{"id":230,"date":"2019-11-14T21:00:37","date_gmt":"2019-11-14T21:00:37","guid":{"rendered":"https:\/\/pressbooks.ccconline.org\/accnursingpharmacology\/chapter\/5-13-leukotriene-receptor-antagonists\/"},"modified":"2025-01-16T22:26:07","modified_gmt":"2025-01-16T22:26:07","slug":"5-13-leukotriene-receptor-antagonists","status":"publish","type":"chapter","link":"https:\/\/pressbooks.ccconline.org\/accnursingpharmacology\/chapter\/5-13-leukotriene-receptor-antagonists\/","title":{"raw":"5.13 Leukotriene Receptor Antagonists","rendered":"5.13 Leukotriene Receptor Antagonists"},"content":{"raw":"Montelukast is a leukotriene antagonist medication with a distinctly-shaped square tablet. See Figure 5.19.[footnote]\u201cSingulair 10mg<\/a>\u201d by FedEx<\/a> is licenced under CC BY-NC-ND 2.0<\/a>[\/footnote]<\/sup>\n\nMechanism of Action: <\/strong>Montelukast blocks leukotriene receptors and decreases inflammation.\n\nIndications: <\/strong>Montelukast is used for the long-term control of asthma and for decreasing the frequency of asthma attacks. It is also indicated for exercise-induced bronchospasm and allergic rhinitis.\n\nNursing Considerations: <\/strong>The medication is safe for children 12 months and older. It is available in granule packets and chewable tablets, as well as regular tablets.\n\nBoxed Warning:<\/strong> Serious mental health side effects, including suicidal ideation. Should be avoided for treating mild asthma unless conventional treatment is ineffective.\n\nSide Effects\/Adverse Effects: <\/strong>Montelukast can cause headache, cough, nasal congestion, nausea, hepatotoxicity, and suicidal ideation.\n\nHealth Teaching & Health Promotion: <\/strong>Clients should be instructed to take medications at the same time each day and at least two hours prior to exercise. They should not discontinue medications without notifying the health care provider.[footnote]uCentral from Unbound Medicine. https:\/\/www.unboundmedicine.com\/ucentral<\/a>[\/footnote]<\/sup>\n\n[caption id=\"attachment_229\" align=\"aligncenter\" width=\"433\"]\"Photo Figure 5.19 Montelukast Tablets[\/caption]\n\nNow let's take a closer look at the medication grid on montelukast in Table 5.13.[footnote]This work is a derivative of Pharmacology Notes: Nursing Implications for Clinical Practice<\/a> by Gloria Velarde<\/a> licensed under CC BY-NC-SA 4.0<\/a>[\/footnote],[footnote]Frandsen, G., & Pennington, S. (2018). Abrams\u2019 clinical drug: Rationales for nursing practice <\/em>(11th ed.). Wolters Kluwer.[\/footnote],[footnote]This work is a derivative of DailyMed<\/a> by U.S. National Library of Medicine<\/a> in the Public Domain<\/a>. [\/footnote],[footnote]Adams, M., Holland, N., & Urban, C. (2020). Pharmacology for nurses: A pathophysiologic approach <\/em>(6th ed.).<\/em> pp. 622-63.[\/footnote]<\/sup>\n\nTable 5.13 Montelukast Medication Grid\n\n\n\n\n
\n
Class\/Subclass<\/strong><\/h5>\n<\/th>\n
\n
Prototype\/Generic<\/strong><\/h5>\n<\/th>\n
\n
Nursing Considerations<\/strong><\/h5>\n<\/th>\n
\n
Therapeutic Effects<\/strong><\/h5>\n<\/th>\n
\n
Side\/Adverse Effects<\/strong><\/h5>\n<\/th>\n<\/tr>\n
Leukotriene Inhibitor<\/strong><\/td>\nmontelukast<\/a><\/td>\nUse as directed; not to be used as a quick relief medication for asthma attacks\n\nTypically, 3-7 days to reach effectiveness\n\nBoxed warning for serious mental health side effects, including suicidal ideation. Should be avoided for treating mild asthma unless conventional treatment is ineffective<\/td>\nPrevention and treatment of asthma and exercise-induced bronchoconstriction<\/td>\nHeadache\n\nCough\n\nNasal congestion\n\nNausea\n\nHepatotoxicity\n\nSuicidal ideation<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n ","rendered":"

Montelukast is a leukotriene antagonist medication with a distinctly-shaped square tablet. See Figure 5.19.[1]<\/sup><\/a><\/sup><\/p>\n

Mechanism of Action: <\/strong>Montelukast blocks leukotriene receptors and decreases inflammation.<\/p>\n

Indications: <\/strong>Montelukast is used for the long-term control of asthma and for decreasing the frequency of asthma attacks. It is also indicated for exercise-induced bronchospasm and allergic rhinitis.<\/p>\n

Nursing Considerations: <\/strong>The medication is safe for children 12 months and older. It is available in granule packets and chewable tablets, as well as regular tablets.<\/p>\n

Boxed Warning:<\/strong> Serious mental health side effects, including suicidal ideation. Should be avoided for treating mild asthma unless conventional treatment is ineffective.<\/p>\n

Side Effects\/Adverse Effects: <\/strong>Montelukast can cause headache, cough, nasal congestion, nausea, hepatotoxicity, and suicidal ideation.<\/p>\n

Health Teaching & Health Promotion: <\/strong>Clients should be instructed to take medications at the same time each day and at least two hours prior to exercise. They should not discontinue medications without notifying the health care provider.[2]<\/sup><\/a><\/sup><\/p>\n

\"Photo
Figure 5.19 Montelukast Tablets<\/figcaption><\/figure>\n

Now let’s take a closer look at the medication grid on montelukast in Table 5.13.[3]<\/sup><\/a>,[4]<\/sup><\/a>,[5]<\/sup><\/a>,[6]<\/sup><\/a><\/sup><\/p>\n

Table 5.13 Montelukast Medication Grid<\/p>\n\n\n\n\n
\n
Class\/Subclass<\/strong><\/h5>\n<\/th>\n
\n
Prototype\/Generic<\/strong><\/h5>\n<\/th>\n
\n
Nursing Considerations<\/strong><\/h5>\n<\/th>\n
\n
Therapeutic Effects<\/strong><\/h5>\n<\/th>\n
\n
Side\/Adverse Effects<\/strong><\/h5>\n<\/th>\n<\/tr>\n
Leukotriene Inhibitor<\/strong><\/td>\nmontelukast<\/a><\/td>\nUse as directed; not to be used as a quick relief medication for asthma attacks<\/p>\n

Typically, 3-7 days to reach effectiveness<\/p>\n

Boxed warning for serious mental health side effects, including suicidal ideation. Should be avoided for treating mild asthma unless conventional treatment is ineffective<\/td>\n

Prevention and treatment of asthma and exercise-induced bronchoconstriction<\/td>\nHeadache<\/p>\n

Cough<\/p>\n

Nasal congestion<\/p>\n

Nausea<\/p>\n

Hepatotoxicity<\/p>\n

Suicidal ideation<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/p>\n

  1. \u201cSingulair 10mg<\/a>\u201d by FedEx<\/a> is licenced under CC BY-NC-ND 2.0<\/a> ↵<\/a><\/li>
  2. uCentral from Unbound Medicine. https:\/\/www.unboundmedicine.com\/ucentral<\/a> ↵<\/a><\/li>
  3. This work is a derivative of Pharmacology Notes: Nursing Implications for Clinical Practice<\/a> by Gloria Velarde<\/a> licensed under CC BY-NC-SA 4.0<\/a> ↵<\/a><\/li>
  4. Frandsen, G., & Pennington, S. (2018). Abrams\u2019 clinical drug: Rationales for nursing practice <\/em>(11th ed.). Wolters Kluwer. ↵<\/a><\/li>
  5. This work is a derivative of DailyMed<\/a> by U.S. National Library of Medicine<\/a> in the Public Domain<\/a>. ↵<\/a><\/li>
  6. Adams, M., Holland, N., & Urban, C. (2020). Pharmacology for nurses: A pathophysiologic approach <\/em>(6th ed.).<\/em> pp. 622-63. ↵<\/a><\/li><\/ol><\/div>","protected":false},"author":83,"menu_order":13,"template":"","meta":{"pb_show_title":"on","pb_short_title":"","pb_subtitle":"","pb_authors":[],"pb_section_license":""},"chapter-type":[48],"contributor":[],"license":[],"class_list":["post-230","chapter","type-chapter","status-publish","hentry","chapter-type-numberless"],"part":186,"_links":{"self":[{"href":"https:\/\/pressbooks.ccconline.org\/accnursingpharmacology\/wp-json\/pressbooks\/v2\/chapters\/230","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pressbooks.ccconline.org\/accnursingpharmacology\/wp-json\/pressbooks\/v2\/chapters"}],"about":[{"href":"https:\/\/pressbooks.ccconline.org\/accnursingpharmacology\/wp-json\/wp\/v2\/types\/chapter"}],"author":[{"embeddable":true,"href":"https:\/\/pressbooks.ccconline.org\/accnursingpharmacology\/wp-json\/wp\/v2\/users\/83"}],"version-history":[{"count":1,"href":"https:\/\/pressbooks.ccconline.org\/accnursingpharmacology\/wp-json\/pressbooks\/v2\/chapters\/230\/revisions"}],"predecessor-version":[{"id":231,"href":"https:\/\/pressbooks.ccconline.org\/accnursingpharmacology\/wp-json\/pressbooks\/v2\/chapters\/230\/revisions\/231"}],"part":[{"href":"https:\/\/pressbooks.ccconline.org\/accnursingpharmacology\/wp-json\/pressbooks\/v2\/parts\/186"}],"metadata":[{"href":"https:\/\/pressbooks.ccconline.org\/accnursingpharmacology\/wp-json\/pressbooks\/v2\/chapters\/230\/metadata\/"}],"wp:attachment":[{"href":"https:\/\/pressbooks.ccconline.org\/accnursingpharmacology\/wp-json\/wp\/v2\/media?parent=230"}],"wp:term":[{"taxonomy":"chapter-type","embeddable":true,"href":"https:\/\/pressbooks.ccconline.org\/accnursingpharmacology\/wp-json\/pressbooks\/v2\/chapter-type?post=230"},{"taxonomy":"contributor","embeddable":true,"href":"https:\/\/pressbooks.ccconline.org\/accnursingpharmacology\/wp-json\/wp\/v2\/contributor?post=230"},{"taxonomy":"license","embeddable":true,"href":"https:\/\/pressbooks.ccconline.org\/accnursingpharmacology\/wp-json\/wp\/v2\/license?post=230"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}